Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

Background The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mutations in the BRAF gene, inhibitors designed specif...

Full description

Bibliographic Details
Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Khin Thway, Kevin J Harrington, Alan A Melcher, Eva Crespo-Rodriguez, Katharina Bergerhoff, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Harriet Whittock, Richard Buus, Syed Haider, Gareth Muirhead, Kate Newbold, Robert S Coffin, Richard G Vile, Dae Kim, Martin McLaughlin, Malin Pedersen
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Online Access:	https://jitc.bmj.com/content/8/2/e000698.full

Similar Items

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
by: Victoria Jennings, et al.
Published: (2022-03-01)

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
by: XuSha Zhou, et al.
Published: (2021-09-01)

The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism
by: Martin McLaughlin, et al.
Published: (2020-03-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling
by: Victoria Jennings, et al.
Published: (2024-07-01)

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion
by: Julia V. Cockle, et al.
Published: (2017-06-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.
by: Shuta Tamura, et al.
Published: (2023-01-01)

p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells
by: Shuta Tamura, et al.
Published: (2023-01-01)

BRAF in Papillary Thyroid Carcinoma
by: Salvatore Giovanni Lanzilotta, et al.
Published: (2007-01-01)

BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
by: Vinay K. Pattalachinti, et al.
Published: (2025-02-01)

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆
by: G.K. In, et al.
Published: (2024-12-01)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
by: Yasar Subutay Peker, et al.
Published: (2018-01-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
by: Blessie Elizabeth Nelson, et al.
Published: (2023-05-01)

Oncolytic viruses: Narcissistic or altruistic arsonists?
by: Luke Kendall, et al.
Published: (2023-06-01)

Braf-Mutant Melanomas: Biology and Therapy
by: Elvira Pelosi, et al.
Published: (2024-12-01)

BRAF: A Two-Faced Janus
by: Pasquale Pisapia, et al.
Published: (2020-11-01)

BRAF mutation in hairy cell leukemia
by: Ahmad Ahmadzadeh, et al.
Published: (2014-09-01)

BRAF mutation in colorectal cancer: An update
by: Colombo Alfredo, et al.
Published: (2023-01-01)

Immunological effects of BRAF+MEK inhibition
by: Paolo A. Ascierto, et al.
Published: (2018-09-01)

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-03-01)

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
by: Laura J. Jenkins, et al.
Published: (2024-03-01)

Detection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreen® FFPE BRAF qPCR assay
by: Anna Lahn Sørensen, et al.
Published: (2023-01-01)

Detection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreen® FFPE BRAF qPCR assay.
by: Anna Lahn Sørensen, et al.
Published: (2023-01-01)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
by: Francesca Del Bufalo, et al.
Published: (2018-11-01)

BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy
by: Ming Li, et al.
Published: (2021-01-01)

Correction: Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-04-01)

Prospects of BRAF/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review
by: Shingo FUJIO, et al.
Published: (2025-05-01)

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01)

Recognition of BRAF by CDC37 and Re-Evaluation of the Activation Mechanism for the Class 2 BRAF-L597R Mutant
by: Dennis M. Bjorklund, et al.
Published: (2022-06-01)

Landscape of BRAF transcript variants in human cancer
by: Maurizio S. Podda, et al.
Published: (2025-09-01)

DETECTION OF SOMATIC MUTATIONS IN THE BRAF GENE BY PYROSEQUENCING
by: O. P. Dribnokhodova, et al.
Published: (2021-10-01)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
by: Ryan J. Sullivan, et al.
Published: (2011-01-01)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
by: Azad Saei, et al.
Published: (2018-09-01)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF...
by: Michael A. Davies
Published: (2014-01-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
by: Polsky David, et al.
Published: (2004-12-01)

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations
by: J. Ros, et al.
Published: (2025-09-01)

Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers
by: S. Pradervand, et al.
Published: (2024-12-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01)